Results 71 to 80 of about 14,072,748 (310)

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Konig, A., Folwaczny, Christian, Schmidt, F., Simperl, C., Schaefer, M., Torok, P., Glas, J., Schiemann, Uwe, Martin, K.   +8 more
core   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

Arthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko, Ray Zhang, Sohini Mukherjee, Puneet Bajaj, Bonnie L. Bermas   +4 more
wiley   +1 more source

Distinct cytokine patterns in Occult Hepatitis C and Chronic Hepatitis C Virus Infection [PDF]

, 2011
Background & Aim: The immunopathogenesis of chronic hepatitis C virus (HCV) infection is a matter of great controversy. The imbalance of T-helper lymphocyte cell cytokine production was believed to play an important pathogenic role in ...
Nashwa Abousamra, Azza Azza Abdel-Aziz, Mona Elhadidy, Mohamed Abd-elmaksoud, Yahia Gad, Nasser Mousa   +5 more
core  

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E. H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

, 2004
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy ...
PEGINTERFERON ALFA A. HBEAG NEGATIVE CHRONIC HEPATITIS B. STUDY GROUP, MARCELLIN P, BONINO, FERRUCCIO, LAU GK   +3 more
core  

Elevated liver enzymes is not an impediment to allopurinol dose escalation: an observational cohort study

Arthritis Care &Research, Accepted Article.
Objective Routine liver enzyme monitoring is advocated while on allopurinol but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzymes in gout patients commenced on allopurinol. Methods 150 patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed ...
May Shuen Tang, Qai Ven Yap, Peter Pak Moon Cheung, Amelia Santosa, Gim Gee Teng   +4 more
wiley   +1 more source

Hepatitis B Genotypes in Chronic Hepatitis B and Lamivudine Therapy

Intervirology, 2003
The influence of hepatitis B virus (HBV) genotypes on the natural history and the response to treatment of patients with chronic hepatitis B are of potential interest. Compared to the patients with HBV genotype C, those with genotype B were of a younger age and had a higher cumulative rate of hepatitis B e antigen (HBeAg) seroconversion during the ...
Tanaka, Y, Lai, CL, Yuen, MF
openaire   +4 more sources

Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis [PDF]

, 2000
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.
Amann, B., Schmidt, F., Schlösser, S., Loeschke, K., Grunze, Heinz, Schäfer, Martin   +5 more
core   +1 more source

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction

Advanced Healthcare Materials, EarlyView.
FeS‐VA@lanifibranor (FVL), an activated hepatic stellate cell (aHSC)‐targeted nanoplatform comprising vitamin A‐functionalized two‐dimensional iron sulfide nanosheets and lanifibranor, is engineered for precision therapy of liver fibrosis. FVL suppresses the TGF‐β signaling pathway by inhibiting SMAD2/3 phosphorylation and induces ferroptosis in aHSCs,
Yinuo Yang, Mengyao Mu, Ke Ren, Hui Liu, Pengju Ma, Yingqi Wang, Mengmeng Zhang, Xueli Xu, Wenzhe Li, Wenshuang Gao, Xiao Sun, Qiang Zhu   +11 more
wiley   +1 more source

METABOLIC AND CARDIOVASCULAR COMORBIDITIES IN BULGARIAN PATIENTS WITH CHRONIC VIRAL B AND C HEPATITIS [PDF]

Journal of IMAB
Recent epidemiologic data on chronic viral B and C hepatitis in Bulgaria are limited.The evolution of these infections depends on liver complications and the presence of nonliver comorbidities.
Radoslava Tsrancheva, Dimitar Stoyanov, Maria Stancheva, Rozita Karakasheva, Blagovest Stoimenov, Ralitsa Pancheva, Svilen Donev, Ventseslav Yordanov, Nikola Stanchev, Ventsislava Pencheva, Diana Stefanova-Petrova   +10 more
doaj   +1 more source